# Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN

> **NCT03683069** · PHASE4 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 90 (actual)

## Conditions studied

- Hypertension
- Genetics Hypertension

## Interventions

- **DRUG:** Eplerenone vs Amlodipine

## Key facts

- **NCT ID:** NCT03683069
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-15
- **Primary completion:** 2023-08-28
- **Final completion:** 2024-01-31
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03683069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03683069, "Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03683069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*